Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.51 |
| ▸ | BCL2L1 | Q07817 | 11/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 10/20 | 0.50 |
| ▸ | BCL2 | P10415 | 3/20 | 0.49 |
| ▸ | APP | P05067 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | FBP1 | P09467 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27490824 | 0.99 | HDAC8 (0.52) | HDAC8BCL2L1MCL1BCL2APP | |
| SCHEMBL6172936 | 0.82 | HDAC8 (0.56) | HDAC8BCL2L1MCL1 | |
| Potassium SCHEMBL6169298 | 0.81 | HDAC8 (0.55) | HDAC8BCL2L1MCL1 | |
| SCHEMBL6172330 | 0.81 | HDAC8 (0.54) | HDAC8BCL2L1MCL1 | |
| SCHEMBL6170460 | 0.78 | FLT1 (0.47) | BCL2L1MCL1BCL2L3MBTL1MEN1 | |
| SCHEMBL14106476 | 0.77 | KMT2A (0.59) | BCL2L1MCL1BCL2L3MBTL1MEN1 | |
| SCHEMBL6172767 | 0.77 | HDAC8 (0.52) | HDAC8BCL2L1MCL1MEN1MAPT | |
| SCHEMBL6168605 | 0.77 | HDAC1 (0.50) | HDAC8BCL2L1MCL1 | |
| SCHEMBL7938312 | 0.76 | APP (0.64) | APPL3MBTL1MEN1MAPTKMT2A | |
| SCHEMBL1840592 | 0.76 | APP (0.60) | HDAC8APPMAPTHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0882718-B1 | BENZIMIDAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 2005-08-31 | — | — | EP | disclosed |
| US-20020082280-A1 | Method of inhibiting neoplastic cells with benzimidazole derivatives | OSI PHARMACEUTICALS, INC. | 2002-06-27 | — | — | US | disclosed |
| US-6352985-B1 | CARDIOVASCULAR DISORDERS OR GASTROINTESTINAL DISORDERS, DIABETES (TYPE II DIABETES), DIABETIC COMPLICATIONS METHOD FOR LOWERING THE BLOOD SUGAR LEVEL OF A PATIENT, | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-03-05 | — | — | US | disclosed |
| US-6348032-B1 | POTENT COMPOUNDS THAT INDUCE APOPTOSIS IN NEOPLASTIC CELLS (BUT NOT SUBSTANTIALLY IN NORMAL CELLS), WITHOUT SUBSTANTIALLY INHIBITING PGE-2. | CELL PATHWAYS, INC. | 2002-02-19 | — | — | US | disclosed |
| US-6211177-B1 | SIDE EFFECT REDUCTION | CELL PATHWAYS, INC. | 2001-04-03 | — | — | US | disclosed |
| US-6166219-A | Benzimidazole derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-12-26 | — | — | US | disclosed |
| EP-0882718-A1 | BENZIMIDAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082280-A1 | Method of inhibiting neoplastic cells with benzimidazole derivatives | MKI67, CCNI, TMBIM6 | HDAC8 183/4885BCL2L1 636/4885MCL1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.